Receive The Newest Study Notifications

 ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been enrolled in its Phase 2 clinical trial,...

Phase 3 NEPTUNE Trial of OV101 Expected to Enroll the First Patients in the Third Quarter of 2019; CGI-I Angelman Syndrome Scale will be the Sole Primary Endpoint Ovid to Review NEPTUNE Trial Details and Additional Pipeline Program Highlights at Today’s R&D Day to...

 X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of 4WHIM, a pivotal Phase 3 global clinical trial of mavorixafor...

ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led...

Myriad Genetics, Inc.  (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first comprehensive cost-effectiveness analysis of the EndoPredict® test compared to other breast cancer...

Scientists at the NIH and FDA Demonstrate Impressive Synergy of MDNA55 with Interferons  Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA;OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce new data on MDNA55 was...

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces two senior appointments to its clinical team. They will lead the Phase 3 program for Verona Pharma’s first-in-class product candidate,...

– Enrollment completed in third cohort of dose-escalation study at leading brain cancer hospitals in US; Investigators indicate interest in expanding study –  Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced completion of enrollment...

Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced completion of patient recruitment in its pre-pivotal, postcoital...

LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced initiation of a Phase 2b study. On June 24th, 2019, the first subject was enrolled in ILiAD Biotechnologies IB-200P multicenter,...

-- Compassionate use results to be presented at UMDF’s Mitochondrial Medicine 2019 symposium -- -- Minovia initiates U.S. operations in Cambridge, Mass. -- -- John Cox named Executive Chairman -- Minovia Therapeutics today announced dosing of the first patient in a...

Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPLD patients Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line dataset from the...

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has received clearance from the...

Global pharmaceutical company expands use of Medidata Rave Clinical Cloud™ to spur growth and innovation Agreement builds on long-standing relationship since 2006 Unified platform approach creates a single source of truth for greater efficiency and accelerated trials...

INNATE PHARMA ANNOUNCES PUBLICATION OF IPH4102 PHASE I CLINICAL TRIAL RESULTS FOR CTCL IN THE LANCET ONCOLOGY         ·Data to date demonstrate high activity and favorable safety profile in Sézary syndrome, an aggressive form of cutaneous T-cell lymphoma (CTCL)...

EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today that it has filed an application with the Drug...

Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome Short bowel syndrome (SBS) is a complex chronic and severe condition associated with reduced or complete loss of...

Global 4WHIM trial marks first-ever Phase 3 study in patients with WHIM syndrome X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the...

SPI-1005 hits pre-specified endpoints resulting in a significant improvement in hearing loss of 65% and 95% relative to placebo Sound Pharmaceuticals today announced positive top-line results from a randomized, double-blind, placebo-controlled, multi-center...

Q2 Solutions, a leading global clinical trial laboratory services organization that helps customers achieve better clinical trial outcomes, conducted a sample tracking proof-of-concept (POC) using distributed ledger technology (DLT, aka "blockchain") in partnership...